Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23143270 | 1.00 | POLB (0.44) | POLBROCK2USP2ALDH1A1NPSR1 | |
| SCHEMBL29896103 | 0.93 | GAA (0.41) | POLBROCK2EPHX2MAPTGSK3B | |
| SCHEMBL27188837 | 0.93 | GAA (0.41) | POLBROCK2EPHX2MAPTGSK3B | |
| SCHEMBL29896188 | 0.91 | SCN2A (0.41) | ROCK2MAPTGSK3B | |
| SCHEMBL27188884 | 0.91 | SCN2A (0.41) | ROCK2MAPTGSK3B | |
| SCHEMBL29896160 | 0.89 | POLB (0.43) | POLBROCK2USP2ALDH1A1NPSR1 | |
| SCHEMBL27220652 | 0.89 | POLB (0.43) | POLBROCK2USP2ALDH1A1NPSR1 | |
| SCHEMBL23143264 | 0.88 | PIK3CA (0.43) | ROCK2EPHX2HDAC1 | |
| SCHEMBL29896091 | 0.88 | ROCK2 (0.41) | ROCK2EPHX2HDAC1HPGDS | |
| SCHEMBL29896173 | 0.88 | PIK3CA (0.43) | ROCK2EPHX2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952344-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-09 | — | — | US | disclosed |
| US-20220340527-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340527-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2A, GRIN2B | POLB 3227/4885ROCK2 4595/4885USP2 4685/4885 |
| US-11952344-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2A, GRIN2B | POLB 3227/4885ROCK2 4595/4885USP2 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.